Biontech Se (BNTX)

$108.23

+6.09

(+5.96%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $101.60
    $108.47
    $108.23
    downward going graph

    6.13%

    Downside

    Day's Volatility :6.33%

    Upside

    0.22%

    downward going graph
  • $76.53
    $131.49
    $108.23
    downward going graph

    29.29%

    Downside

    52 Weeks Volatility :41.8%

    Upside

    17.69%

    downward going graph

Returns

PeriodBiontech SeSector (Health Care)Index (Russel 2000)
3 Months
24.07%
-6.9%
0.0%
6 Months
5.8%
-1.7%
0.0%
1 Year
10.48%
10.4%
0.0%
3 Years
-66.36%
8.8%
-24.1%

Highlights

Market Capitalization
24.5B
Book Value
$79.73
Earnings Per Share (EPS)
-2.05
PEG Ratio
0.04
Wall Street Target Price
128.818
Profit Margin
-15.36%
Operating Margin TTM
1.68%
Return On Assets TTM
-1.24%
Return On Equity TTM
-2.4%
Revenue TTM
3.0B
Revenue Per Share TTM
12.62
Quarterly Revenue Growth YOY
39.0%
Gross Profit TTM
16.1B
EBITDA
-274.5M
Diluted Eps TTM
-2.05
Quarterly Earnings Growth YOY
0.23
EPS Estimate Current Year
-3.04
EPS Estimate Next Year
-3.4
EPS Estimate Current Quarter
-1.67
EPS Estimate Next Quarter
3.31

Analyst Recommendation

Buy
    54%Buy
    37%Hold
    8%Sell
Based on 24 Wall street analysts offering stock ratings for Biontech Se(by analysts ranked 0 to 5 stars)
Based on 24 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
14
13
Hold
9
9
9
Sell
2
1
1

Analyst Forecast

What analysts predicted

Upside of 19.02%

Current $108.23
Target $128.82

Company Financials

FY18Y/Y Change
Revenue
145.1M
↑ 107.11%
Net Income
-54.6M
↓ 43.94%
Net Profit Margin
-37.64%
↑ 101.41%
FY19Y/Y Change
Revenue
120.7M
↓ 14.88%
Net Income
-199.1M
↑ 273.13%
Net Profit Margin
-165.0%
↓ 127.36%
FY20Y/Y Change
Revenue
586.7M
↑ 344.17%
Net Income
18.5M
↓ 108.48%
Net Profit Margin
3.15%
↑ 168.15%
FY21Y/Y Change
Revenue
21.5B
↑ 3834.42%
Net Income
11.6B
↑ 67613.82%
Net Profit Margin
54.24%
↑ 51.09%
FY22Y/Y Change
Revenue
18.3B
↓ 8.78%
Net Income
10.0B
↓ 8.34%
Net Profit Margin
54.5%
↑ 0.26%
FY23Y/Y Change
Revenue
4.2B
↓ 77.94%
Net Income
1.0B
↓ 90.14%
Net Profit Margin
24.36%
↓ 30.14%
Q2 FY23Q/Q Change
Revenue
971.1M
↓ 29.89%
Net Income
174.2M
↓ 68.02%
Net Profit Margin
17.94%
↓ 21.39%
Q3 FY23Q/Q Change
Revenue
1.6B
↑ 65.2%
Net Income
488.8M
↑ 185.12%
Net Profit Margin
30.96%
↑ 13.02%
Q4 FY23Q/Q Change
Revenue
1.6B
↑ 0.0%
Net Income
499.5M
↑ 0.0%
Net Profit Margin
30.96%
↑ 0.0%
Q1 FY24Q/Q Change
Revenue
203.9M
↓ 87.32%
Net Income
-342.5M
↓ 168.81%
Net Profit Margin
-167.96%
↓ 198.92%
Q2 FY24Q/Q Change
Revenue
138.5M
↓ 31.4%
Net Income
-869.2M
↑ 156.36%
Net Profit Margin
-627.66%
↓ 459.7%
Q3 FY24Q/Q Change
Revenue
1.2B
↑ 867.21%
Net Income
198.1M
↓ 124.52%
Net Profit Margin
15.91%
↑ 643.57%
FY18Y/Y Change
Total Assets
742.8M
↑ 74.26%
Total Liabilities
439.1M
↓ 8.73%
FY19Y/Y Change
Total Assets
886.4M
↑ 22.15%
Total Liabilities
338.0M
↓ 21.2%
FY20Y/Y Change
Total Assets
2.8B
↑ 190.68%
Total Liabilities
1.2B
↑ 211.28%
FY21Y/Y Change
Total Assets
17.9B
↑ 582.77%
Total Liabilities
4.5B
↑ 315.84%
FY22Y/Y Change
Total Assets
24.6B
↑ 47.05%
Total Liabilities
3.4B
↓ 18.13%
FY23Y/Y Change
Total Assets
25.1B
↓ 1.17%
Total Liabilities
3.0B
↓ 14.37%
Q2 FY23Q/Q Change
Total Assets
24.1B
↑ 0.58%
Total Liabilities
2.5B
↑ 29.04%
Q3 FY23Q/Q Change
Total Assets
24.6B
↑ 3.6%
Total Liabilities
2.9B
↑ 17.95%
Q4 FY23Q/Q Change
Total Assets
25.1B
↑ 0.0%
Total Liabilities
3.0B
↑ 0.0%
Q1 FY24Q/Q Change
Total Assets
24.2B
↓ 3.26%
Total Liabilities
2.5B
↓ 17.09%
Q2 FY24Q/Q Change
Total Assets
23.9B
↓ 0.08%
Total Liabilities
3.4B
↑ 38.32%
Q3 FY24Q/Q Change
Total Assets
22.4B
↑ 0.73%
Total Liabilities
3.3B
↑ 3.83%
FY18Y/Y Change
Operating Cash Flow
-66.2M
↑ 10.69%
Investing Cash Flow
-75.6M
↑ 26.46%
Financing Cash Flow
415.4M
↓ 22326.23%
FY19Y/Y Change
Operating Cash Flow
-220.6M
↑ 241.25%
Investing Cash Flow
-85.7M
↑ 16.05%
Financing Cash Flow
425.9M
↑ 4.96%
FY20Y/Y Change
Operating Cash Flow
-16.4M
↓ 93.21%
Investing Cash Flow
-176.2M
↑ 87.83%
Financing Cash Flow
1.1B
↑ 133.43%
FY21Y/Y Change
Operating Cash Flow
1.0B
↓ 6703.09%
Investing Cash Flow
-640.0M
↑ 290.82%
Financing Cash Flow
106.5M
↓ 89.47%
Q2 FY23Q/Q Change
Operating Cash Flow
879.9M
↓ 219.75%
Investing Cash Flow
-1.3B
↑ 0.0%
Financing Cash Flow
-337.3M
↑ 6.76%
Q3 FY23Q/Q Change
Operating Cash Flow
908.4M
↑ 4.89%
Investing Cash Flow
-1.3B
↑ 0.0%
Financing Cash Flow
-13.8M
↓ 95.85%

Technicals Summary

Sell

Neutral

Buy

Biontech Se is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biontech Se
Biontech Se
-2.39%
5.8%
10.48%
-66.36%
407.41%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-22.64%
-24.32%
-6.91%
15.67%
106.43%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-16.76%
63.55%
51.52%
31.97%
130.85%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.17%
0.63%
27.5%
148.14%
106.59%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.38
18.38
1.11
44.91
0.17
0.07
NA
272.04
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biontech Se
Biontech Se
Buy
$24.5B
407.41%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.7B
106.43%
18.38
33.61%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.1B
130.85%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.2B
106.59%
32.84
-4.51%

Insights on Biontech Se

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 128.7M → 1.24B (in $), with an average increase of 89.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -807.8M → 198.1M (in $), with an average increase of 507.8% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 51.5% return, outperforming this stock by 41.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.0% return, outperforming this stock by 98.4%

Institutional Holdings

  • Baillie Gifford & Co Limited.

    3.47%

  • FMR Inc

    2.63%

  • PRIMECAP Management Company

    1.88%

  • Flossbach von Storch AG

    1.82%

  • Harding Loevner L.P.

    1.22%

  • Morgan Stanley - Brokerage Accounts

    0.96%

Corporate Announcements

  • Biontech Se Dividends September,2022

    In the quarter ending September,2022. Biontech Se has declared dividend of $2.11

    Read More

Company Information

everyone achieves greatness at biontech! as one of the most rapidly growing biotechnology companies in europe, we’re working on revolutionary approaches in the fight against cancer and other diseases. over 400 dedicated, passionate pioneers achieve sensational success and promising breakthroughs time and again by forging new paths – and ensure people all around the world have hope for the future. you too can become a pioneer! http://biontech.de/ http://biontech.de/imprint/

Organization
Biontech Se
Employees
6133
CEO
Dr. Ugur Sahin M.D.
Industry
Health Technology

FAQs